NCT02964702 (TRON1-Japan) is a NA clinical trial of Thrombectomy Device T-01 in Acute Ischemic Stroke, sponsored by JIMRO Co., Ltd..

Who is sponsoring NCT02964702?

NCT02964702 is sponsored by JIMRO Co., Ltd..

What drugs are being tested in NCT02964702?

Interventions in NCT02964702: Thrombectomy Device T-01.

What condition does NCT02964702 study?

NCT02964702 studies Acute Ischemic Stroke.

Is NCT02964702 still recruiting?

NCT02964702 is currently completed. Last updated 18 July 2019.

Last reviewed 2019-07-18 · How we verify

NCT02964702: TRON1-Japan

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)

Completed NA Last updated 18 July 2019

What this trial tests

NA trial testing Thrombectomy Device T-01 in Acute Ischemic Stroke in 50 participants. Completed in 23 October 2017.

Timeline

9 November 2016

Primary endpoint
25 July 2017

23 October 2017

Quick facts

Lead sponsor	JIMRO Co., Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	9 November 2016
Primary completion	25 July 2017
Estimated completion	23 October 2017
Sites	13 locations across Japan

Drugs / interventions tested

Thrombectomy Device T-01

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

JIMRO Co., Ltd.

Who can join

Adults 20 to 85, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of catheter-based thrombectomy for reperfusion by removing a thrombus in a cerebral blood vessel in patients with acute cerebral infarction (within 8 hours after onset), in whom intravenous administration of tissue plasminogen activator (t-PA) is not indicated or reperfusion cannot be achieved by intravenous t-PA administration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other JIMRO Co., Ltd. trials

Trials by the same sponsor.

NCT03189641 — Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02964702 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by JIMRO Co., Ltd.
Last refreshed: 18 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02964702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing